IQ EQ FUND MANAGEMENT IRELAND Ltd Reduces Position in Stryker Co. (NYSE:SYK)

IQ EQ FUND MANAGEMENT IRELAND Ltd trimmed its stake in Stryker Co. (NYSE:SYK) by 16.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,714 shares of the medical technology company’s stock after selling 3,600 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Stryker were worth $6,378,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. J. W. Coons Advisors LLC lifted its holdings in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after purchasing an additional 26 shares during the last quarter. Mascoma Wealth Management LLC increased its position in Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock valued at $53,000 after buying an additional 27 shares in the last quarter. Opal Wealth Advisors LLC raised its stake in Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after buying an additional 28 shares during the last quarter. Lindbrook Capital LLC grew its stake in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock worth $507,000 after acquiring an additional 28 shares during the last quarter. Finally, Capital & Planning LLC increased its holdings in shares of Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 29 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Down 1.5 %

SYK opened at $367.34 on Thursday. The company has a fifty day moving average of $384.74 and a two-hundred day moving average of $374.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a market capitalization of $140.17 billion, a price-to-earnings ratio of 47.34, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. On average, research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Argus set a $450.00 price objective on shares of Stryker in a report on Monday, February 3rd. Barclays raised their target price on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. raised their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.